Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite its doing so, one could argue that the drugmaker, which isn't that far off from its 52-week high, is still worth buying at current levels, given the company's prospects and upside potential. Let's discuss recent developments with Regeneron and determine why the company's shares are still worth buying.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles